Slide 1: Media and financial analysts conference Financial year 2025
Media and financial analysts conference Financial year 2025 Dominik Arnold, CEO Markus Abderhalden, CFO 6th March 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This written statement and oral statements or other statements made, or to be made, by us contain forward- looking statements that do not relate solely to historical or current facts. These forward-looking statements are based on the current plans and expectations of our manage
Slide 3: Agenda
Agenda Media and financial analysts conference full year 2025 Highlights 2025 Dominik Arnold, CEO Financials 2025 Markus Abderhalden, CFO Outlook Dominik Arnold, CEO Q&A All Full Year Results 2025 3
Slide 4: Highlights 2025
Highlights 2025 COLTENE strong HY2 confirms go-to-market strategy Key figures • Net sales CHF 240.0m (PY CHF 250.2m); -0.2% adjusted for FX and -4.0% in CHF • HY2 with strong growth of 4.7% in local currencies • EBIT margin at 8.8% (PY 10.7%) • Net profit amounted to CHF 14.9m (PY CHF 20.5m) • Fre
Slide 5: Financial summary 2025
Financial summary 2025 Stable sales with lower profitability and cash flow Sales • Net sales down by 4.0% to CHF 240.0m • In local currencies net sales decreased by 0.2% EBIT • EBIT decreased to CHF 21.0m (-21.7% vs PY) • EBIT margin at 8.8% (PY 10.7%) Net profit • Net profit decreased to CHF
Slide 6: Income statement
Income statement Net income decreased due to lower sales, weaker gross margin and higher financial expenses (FX) in CHF million 2025 % 2024 % % YoY • Net sales: The decrease is mainly due to a further Net sales 240.0 100.0 250.2 100.0 -4.0 strengthening of the Swiss Franc. Other operating income 0.5
Slide 7: Net sales by product area
Net sales by product area Infection Control with a slight growth despite the general reluctance in equipment spendings Net sales 2025 by product area (shares) Net sales 2025 by product area (in CHF m) -0.6% +0.1 99 Treatment Auxiliaries 96 (2024: 39.5%) 85 2024 Infection Control 80 0.0% 2025 (2024:
Slide 8: Net sales by region
Net sales by region EMEA with a growth of 1.5% increased its share of sales to 36.8% Net sales 2025 by region (shares) Net sales 2025 by region (in CHF million) ASIA -1.3% (2024: 10.4%) LATAM 122 (2024: 5.8%) 10.2% +1.5% 113 2024 5.9% EMEA 2025 87 88 (2024: 34.9%) 36.8% -1.1% +0.4% 26 24 14 14 47.1%
Slide 9: EBIT development 2024 – 2025
EBIT development 2024 – 2025 In CHF million 26.8 6.7 21.0 0.3 0.3 2.7 1.9 EBIT 2024 Volume effect Margin effect Personnel expenses Other operating Depreciation & EBIT 2025 expense Amortization Gross profit: Negativ volume effect driven Personnel expenses: The inflation-based Other OPEX were reduced
Slide 10: Net profit
Net profit Lower tax rate could more than offset the negative impact from FX Lower financial result: Tax rate decrease: Net profit decrease: Higher foreign exchange losses Lower taxable profit in countries Net profit mostly driven by lower EBIT (CHF -2.5m) with higher tax rates while the negat
Slide 11: Balance sheet
Balance sheet Healthy balance sheet with a strong equity ratio in CHF million 31.12.2025 31.12.2024 % YoY • Increase of receivables due to higher sales in Cash & cash equivalents 20.6 21.9 -5.5 the last quarter. Receivables 48.8 44.0 9.8 • Decrease in inventory due to the FX Inventory 57.5 60.4 -4.9
Slide 12: Equity
Equity Continuous strong financial position provides room for inorganic growth In CHF million Total assets decreased to CHF 183.3m mainly due to FX development Equity ratio decreased to 54.9% 300 58.2% 60 54.9% 250 50 200 187 183 40 150 78 83 30 100 20 50 109 101 10 0 0 31.12.2024 31.12.2025 Equ
Slide 13: Cash flow statement
Cash flow statement Weak free cash flow due to lower net profit in CHF million 2025 2024 % YoY • Operating cash flow below PY due to Net profit 14.9 20.5 -27.0 lower net profit and a temporary Depreciation and amortization 7.2 6.9 increase in NWC. Other non cash items 5.3 6.1 • Cash out from investi
Slide 14: Strategic direction: COLTENE preserves natural teeth
Strategic direction: COLTENE preserves natural teeth Dedicated business units with their own distinct value propositions Dental Preservation Treatment Auxiliaries Infection Control Dental Preservation Treatment Auxiliaries Infection Control in dentistry Markets Emphasizing the benefits of High p
Slide 15: COLTENE: Saving Teeth. Made Simple.
COLTENE: Saving Teeth. Made Simple. Unlocking value across the full Endodontic to Restoration workflow. 1. Endo on autopilot A guided, intuitive endodontic workflow enabling efficient & predictable treatment. Reduced chair B6.5 CHF time and increased confidence for general Endodontics, Restoratives
Slide 16: SciCan: Smart Steri-Center. Made Simple.
SciCan: Smart Steri-Center. Made Simple. Unlocking value across the Infection Control workflow. 1. The full solution A full end-to-end ecosystem — from surface disinfection to automated washing and sterilization — delivering enhanced digital traceability, safer B1.5 CHF Infection Control market outc
Slide 17: Focus areas in 2026
Focus areas in 2026 Driving for profitable growth - Execute on digital marketing, education and sales to bring our unique workflow offering from Endo to Resto (E2R) better to the Value creation with market innovation and new way to market - Execute on providing unique value and support to dentists a
Slide 18: Outlook
Outlook Focus on innovation and sustainable growth Outlook 2026 • Short-term outlook remains highly volatile due to geopolitical situation with uncertain impact on the world economy • Sales growth in the low single digits (in local currencies) • EBIT margin of 9% - 10% Medium-term targets confir
Slide 19: Mission
Mission “We enable dentists to preserve natural teeth efficiently and safely. We empower our teams to deliver exceptional outcomes with reliable dental solutions, education, and personal support, creating positive impacts for patients, dentists, and partners.” “We preserve natural teeth” The Swiss w
Slide 20: VUU UU UU UU U-@
| \ VUU UU UU UU U-@ pnp tt tote ta COLTENE
Slide 21: Organization
Organization Management Board of Directors Group Management Matthias Altendorf Dominik Arnold Chairman CEO Markus Abderhalden Mattias Flodin Jürgen Rauch Allison Zwingenberger CFO CMO Paul Frey Di Hu Astrid Waser Daniel Bühler CSO NAM CSO Europe/ ROW Gregor Picard Edgar Schönbächler Martin Schaufelb
Slide 22: COLTENE overview
COLTENE overview Toronto (Canada) Altstätten (Switzerland) Top quality dental supplier • COLTENE develops, manufactures and markets premium dental materials and small equipment for dental practices Infection Control Dental Improvement/Treatment Auxiliaries • 6 specialized manufacturing sites Cuyahog
Slide 23: Key reasons to invest in COLTENE
Key reasons to invest in COLTENE Positioning of COLTENE shares Dental market with structural growth COLTENE operates in an Positioned to withstand economic downturns attractive market Ensures a continuous strong FCF Broad product portfolio with trusted brands COLTENE operates on a Strong f
Slide 24: Summary
Summary Our focus Value creation • Dental Preservation: Making dental preservation simpler, safer, faster and more economical than surgical treatments • Treatment Auxiliaries: Provide best price/performance for dental treatment auxiliaries • Infection Control: Become market leader in NAM with digita
Slide 25: Conclusion
Conclusion The preferred supplier to improve and preserve natural teeth Key financial figures in CHF (in 2028) • COLTENE operates in a stable market Sales • COLTENE provides value that resonates with 3-5% p.a. patients, dentists and dental business owners • COLTENE has three distinct businesses with
Slide 26: Key figures
Key figures Five-year overview 2021 - 2025 Net sales in CHF million EBIT in CHF million EBIT EBIT Margin in % 300 279.2 267.1 50 1.0 250.2 43.8 250 242.7 240.0 40 34.9 0.8 200 30 26.8 0.6 150 19.6 21.0 20 13.1 0.4 100 50 10 15.7 0.2 8.1 10.7 8.8 0 0 0.0 2021 2022 2023 2024 2025 2021 2022 2023 2024 2
Slide 27: Share performance
Share performance Continued volatility in the financial market environment Share price Earnings per share/dividend Share price performance (03.01.2024 to 03.02.2026) Earnings per Share Dividend CLTN nominal shares/Swiss Performance Index (SPI) adjusted 5.3 4.4 3.3 3.3 3.4 2.5 2.5 2.0 2.0 2.0* 2021 2